TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04197986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Participants randomly assigned to infigratinib will receive hard gelatin capsules for oral administration of infigratinib 125 mg once a day (administered as one 100-mg capsule and one 25-mg capsule) using a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomly assigned to placebo will receive placebo matching in appearance the investigational product (infigratinib), which will be provided as hard gelatin capsules for oral use and will be administered once daily on a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
Study: NCT02960698

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IRM and comportemental tasks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IRM and comportemental tasks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IRM and comportemental tasks
Study: NCT00653913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCH 58235
Description: SCH 58235 10 mg (once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCH 58235
Description: SCH 58235 10 mg (once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCH 58235
Description: SCH 58235 10 mg (once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCH 58235
Description: SCH 58235 10 mg (once daily)
Study: NCT04707079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Eligible subjects will be given duvelisib orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
Study: NCT02575144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 500mg PO twice daily on days 1-28 for a 28-day cycle
Study: NCT00653913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCH 58235
Description: SCH 58235 10 mg (once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCH 58235
Description: SCH 58235 10 mg (once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin
Description: Pitavastatin 2 mg (once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin
Description: Pitavastatin 2 mg (once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin
Description: Pitavastatin 2 mg (once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin
Description: Pitavastatin 2 mg (once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin
Description: Pitavastatin 2 mg (once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin
Description: Pitavastatin 2 mg (once daily)
Study: NCT02849249

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: allergovac polimerized (100/100)
Description: Patients will recieve a initiation phase plus a mantenaince phase for 3 months of an allergy vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: allergovac polimerized (100/100)
Description: Patients will recieve a initiation phase plus a mantenaince phase for 3 months of an allergy vaccine.
Study: NCT00475540

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: synthetic monofilament polypropylene mesh
Description: Vaginal prolapse repair with mesh

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: synthetic monofilament polypropylene mesh
Description: Vaginal prolapse repair with mesh
Study: NCT03027843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: in GH group, patients have weekly injections of GH dose 14 iu, until the day of hCG.
Study: NCT04257227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The rTMS intervention will be performed in a dedicated rTMS patient room on the PC unit, where the patient can remain in their bed seated upwards at a 45 degree angle, or seated in a chair.~The stimulation intensity for treatment will be determined by measuring the resting and active motor threshold (rMT and aMT) using single pulse TMS over the motor cortex using standard techniques as in previous trials. Investigators will use left-sided intermittent theta burst stimulation (iTBS). The trained team member will locate the left DLPFC using the BeamF3 technique. For the open-label dose-finding study, this region will be stimulated intermittently at 3 TMS pulses every 200 milliseconds for 2 seconds (i.e. 30 stimulations). This procedure is repeated every 10 seconds for a total duration of 3 minutes during which 600 total pulses are delivered. Participants will receive up to 8 3-minute sessions daily at 45 minute intervals for 5 days (consecutively or in a seven-day window if need be).
Study: NCT03026049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep venous stenting
Description: Deep venous stent
Study: NCT01714011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.~Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours.
Study: NCT03240718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: CORE fractional CO2 laser treatment
Study: NCT02575144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of \>60 cc/min
Study: NCT00532428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: 60 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: 120 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01352065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: tablet, 250 mg per day, twice per day, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: tablet, 10 mg per day, single per day, 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 10 mg per day, single per day, 8 weeks
Study: NCT02575144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: 25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of \>60 cc/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
Study: NCT01804036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Week 1: 10 mg Zolpidem daily for 1 week, Week 2: 10 mg Zolpidem daily for one week, taken as needed, Week 3: 5 mg Zolpidem daily for 1 week, taken as needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging
Description: An awareness training program. One 2 hr class per week for 3 weeks - 2 hours per session
Study: NCT01768468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAYLA tablet
Description: 1 tablet twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JOINS tablet
Description: 1 tablet at each time, 3 times a day
Study: NCT04718324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-PROMS
Description: Participants randomised to the e-PROMS arm will receive a safe link to the e-PROMS and a unique identification number in the electronic form, so as to preserve anonymity. This is a one-time intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: p-PROMS
Description: Participants randomised to the p-PROMS arm will receive the PROMS and PREMS questionnaires and a unique identification number in paper form.
Study: NCT04492878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKERVIS®1mg/mL
Description: One drop of study medication once daily in each eye at bedtime during 90 days.
Study: NCT02993458

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet
Description: DASH style diet rich in fruits, vegetables, and low-fat dairy foods and low in saturated fat and total fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: DASH style diet rich in fruits, vegetables, and low-fat dairy foods and low in saturated fat and total fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Na diet
Description: Sodium intake of 1500 mg/d (65 mmol, or 0.75 mg/Kcal/d), representing the Adequate Intake recommended by the Institute of Medicine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Na diet
Description: Sodium intake of 1500 mg/d (65 mmol, or 0.75 mg/Kcal/d), representing the Adequate Intake recommended by the Institute of Medicine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Na diet
Description: Sodium intake of 3500 mg/d (152 mmol, or 1.73 mg/Kcal/d, representing the highest sodium intake used for adults in the DASH Sodium trial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Na diet
Description: Sodium intake of 3500 mg/d (152 mmol, or 1.73 mg/Kcal/d, representing the highest sodium intake used for adults in the DASH Sodium trial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Diet
Description: The usual diet will include foods that provide the majority of energy for adolescents in the U.S., i.e. grain based desserts, pizza, sugary drinks,pasta, chicken, and chicken mixed dishes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Diet
Description: The usual diet will include foods that provide the majority of energy for adolescents in the U.S., i.e. grain based desserts, pizza, sugary drinks,pasta, chicken, and chicken mixed dishes.
Study: NCT01017887

Intervention type: DEVICE
Intervention: Airseal access port for laparoscopic surgery
Description: The investigators will utilize this access port that is already approved by the FDA for it's intended use in laparoscopic surgery. The investigators are simply measuring the percentage of carbon dioxide in the peritoneal cavity.

Intervention type: DEVICE
Intervention: Standard Laparoscopy ports
Description: Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.

Intervention type: DEVICE
Intervention: Standard Laparoscopy ports
Description: Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.
Study: NCT00966693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given PO
Study: NCT01928992

Intervention type: DEVICE
Intervention: 3D
Description: subjects that underwent 3D mammography

Intervention type: DEVICE
Intervention: 2D
Description: those subjects that underwent 2D mammography
Study: NCT01714011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole and to a lesser extent, to its major metabolite, dehyrdro-aripiprazole. Steady state concentrations are attained with in 14 days of dosing. The mean elimination half lives are about 75 hours and 95 hours respectively. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Absorption of aripiprazole is not affected by food.
Study: NCT02695225

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lay-led tobacco abstinence
Description: Lay-led tobacco abstinence: Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lay-led promotion of Ohio Quit Line
Description: Lay-led promotion of Ohio Quit Line (control condition): Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
Study: NCT03089970

Intervention type: DIAGNOSTIC_TEST
Intervention: Exhaled breath condensate collection
Description: Breath from humans is cooled, condensed, and collected

Intervention type: DIAGNOSTIC_TEST
Intervention: Exhaled breath condensate collection
Description: Breath from humans is cooled, condensed, and collected

Intervention type: DIAGNOSTIC_TEST
Intervention: Exhaled breath condensate collection
Description: Breath from humans is cooled, condensed, and collected
Study: NCT02575144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
Study: NCT04344184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-ascorbic acid
Description: 50 mg/kg intravenous vitamin C infusion every 6 hours for up to 96 hours
Study: NCT03556748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole-body electromyostimulation
Description: WB-EMS training is performed 2x/week for a total of 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
Study: NCT00002718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01292044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastography
Description: A conventional thyroid echography performed before a the time of fine needle aspiration will include elastographic measurements for each node under study.
Study: NCT00795509

Intervention type: DRUG
Intervention: Tolterodine tartrate
Description: Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability.
Study: NCT02282176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin IV 10mg/kg daily for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Azithromycin placebo (5% Dextrose) daily for 10 days
Study: NCT02146833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Comparison of different dosages and dosing schedules of drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Comparison of different dosages and dosing schedules of drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Comparison of different dosages and dosing schedules of drug.
Study: NCT02013089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib or Gefitinib
Description: Erlotinib 150mg talbet or Gefitinib 250 mg tablet per day for patients with EGFR gene alternation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10 mg orally once daily every day for patients with mTOR gene alternation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400 mg tablet orally per day for patietns with KIT, PDGFR, ABL gene alternation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib or Sunitinib
Description: Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day with or without food for patients with VEGFR, KIT, RAF gene alternation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Vandetanib 300 mg orally once daily for patients with RET gene fusion.
Study: NCT05221788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic therapy
Description: Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If SV increased \>10%, 200 ml of electrolyte solution was continued until SV increased \<10%. After fluid shock, if SV increases \<10% but mean arterial pressure (MAP) \<65 mmHg and/or cardiac index (CI) \<2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output \<0.5 ml /kg/h and/or heart rate more than 20% above baseline), plasma was administered until urine output and/or HR returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
Study: NCT02356640

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided celiac ganglion neurolysis
Description: EUS-CGN would be performed with a linear video echoendoscope (Olympus UM 2000; Olympus Co Ltd, Japan). The celiac ganglia are visualized under linear EUS and the injection would be applied directly into the ganglia. It is represented by small 2 to 3 mm hypoechoic nodules with hyperechoic foci in the center or a single elongated hypoechoic structure. IIf the ganglia are not identified by EUS, then injection would be performed as bilateral injections at the celiac vessel trunk. All procedures would be performed by a two experienced endosonographer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous celiac plexus neurolysis
Description: Percutaneous fluoroscopy-guided CPN would be performed in the operation theatre with the transcural technique. A 22-gauge, 17 cm-long spinal needle (B-D Quincke Type Point, Becton Dickinson \&Co., NJ 07417, USA) would be inserted and advanced just caudal to the margin of 12th rib and cephalad to the transverse process of L1 toward the anterolateral surface of the L1 vertebral body. Final needle position would be confirmed by radiographic contrast, layering over anterior surface of aorta. 10mL of levobupivacaine (0.25%), followed by 10mL of absolute alcohol would be injected on both sides using separate punctures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Olympus UM 2000

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B-D Quincke Type Point

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Study: NCT04045626

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corneal cross-linking
Description: Riboflavin is instilled over cornea followed by Ultraviolet-A irradiation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corneal cross-linking
Description: Riboflavin is instilled over cornea followed by Ultraviolet-A irradiation
Study: NCT02079558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Carbetocin with single 100 microg IV dosage was used in this investigation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin with 30 international units (IU) IV infusion was used in this investigation
Study: NCT03225937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab, Lapatinib
Description: Patients enrolled in Cohort A will receive lapatinib 1000 mg daily per os + trastuzumab 4 mg/kg iv load, followed by 2 mg/kg iv weekly. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab-emtansine
Description: Patients enrolled in Cohort B will receive pertuzumab 840 mg iv load, followed by 420 mg iv Q3weeks + trastuzumab-emtansine 3.6 mg/kg iv on day 1 of each subsequent 3 week cycle.~Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.
Study: NCT01928563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Study: NCT04344184

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose 5% Water
Study: NCT01928563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil+Dapoxetine
Study: NCT02030821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amicar
Description: Subjects randomized to receive Amicar will receive this during surgical intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TXA
Description: Subjects randomized to receive TXA will receive this during surgical intervention
Study: NCT04861714

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regeneten
Description: Augmentation of standard subscapularis repair with regeneten patch

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard repair
Description: Standard subscapularis repair
Study: NCT02153489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo